Verastem, Inc. Files Q1 2025 10-Q
Ticker: VSTM · Form: 10-Q · Filed: May 13, 2025 · CIK: 1526119
| Field | Detail |
|---|---|
| Company | Verastem, INC. (VSTM) |
| Form Type | 10-Q |
| Filed Date | May 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals, financing
TL;DR
Verastem's Q1 2025 10-Q is in. Check R&D and recent financing rounds.
AI Summary
Verastem, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial performance and business activities, including details on its research and development expenses and fair value adjustments. Key events mentioned include a private placement in April 2025 and a public offering in July 2024.
Why It Matters
This filing provides investors with an update on Verastem's financial health and strategic activities during the first quarter of 2025, impacting their investment decisions.
Risk Assessment
Risk Level: medium — The company operates in the pharmaceutical sector, which is inherently risky due to regulatory hurdles and research & development uncertainties.
Key Numbers
- 20250331 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 20250513 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Verastem, Inc. (company) — Filer of the 10-Q
- March 31, 2025 (date) — End of the reporting period
- 20250331 (date) — Conformed period of report
- 20250513 (date) — Filing date
- Needham, MA (location) — Company's business address
- Genfleet Therapeutics Shanghai Inc. (company) — Mentioned in relation to option exercise
FAQ
What were Verastem's primary R&D expenses during the period ending March 31, 2025?
The filing references 'ResearchAndDevelopmentExpense' from us-gaap/2024, indicating these are a significant focus, though specific dollar amounts for the quarter are not detailed in this header.
Did Verastem engage in any financing activities in April 2025?
Yes, the filing mentions 'vstm:PrivatePlacement2025Member' associated with the date '2025-04-25', indicating a private placement occurred.
What is the company's fiscal year end?
Verastem, Inc.'s fiscal year ends on December 31st.
When did Verastem conduct its July 2024 Public Offering?
The filing indicates activities related to 'vstm:July2024PublicOfferingMember' occurred between '2025-03-01' and '2025-03-31', and also between '2024-12-01' and '2024-12-31'.
Is there any mention of Verastem's involvement with Genfleet Therapeutics Shanghai Inc.?
Yes, the filing mentions 'vstm:GenfleetTherapeuticsShanghaiIncMember' in the context of 'srt:MaximumMember' and 'vstm:ExerciseOfAllThreeGenFleetOptionsMember' on '2023-08-24'.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding Verastem, Inc. (VSTM).